Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2022 Dec 1;37(2):452. doi: 10.1111/jdv.18750

Corrigendum

PMCID: PMC10117614  PMID: 36453829

In the article by B.M. Piraccini et al. 1 , there is an error in the subsection entitled “Safety assessment” on page 291.

The incorrect sentence reads:

Withdrawal rates due to treatment‐related TEAEs were 2.8% and 2.2% in the topical finasteride and placebo groups, respectively, and 7.1% in the topical finasteride group.

The correct sentence should read:

Withdrawal rates due to treatment‐related TEAEs were 2.8% and 2.2% in the topical finasteride and placebo groups, respectively, and 7.1% in the oral finasteride group.

Reference

  • 1. Piraccini BM, Blume‐Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36:286–94. 10.1111/jdv.17738 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the European Academy of Dermatology and Venereology are provided here courtesy of Wiley

RESOURCES